Since the 1990s, mad cow disease occurred one after another in Europe and the United States. In order to ensure the quality and safety of heparin products, European and American pharmaceutical manufacturers completely stopped purchasing heparin extracted from the intestines and lungs of cattle in Europe and The United States, which objectively promoted the stable and rising price of pig intestinal heparin in China. At the end of March 2010, the global influenza A (H1N1) broke out in Mexico and the southwest of the United States, and the international market erected a barrier to the export of Heparin from Mexico. With the loss of The market share of Heparin from Mexico, a large number of purchase orders of heparin were concentrated in China, and the demand for heparin increased at that time. Major heparin export enterprises have also increased the purchase price in order to win more heparin supplies.
The 21st century is an age of aging population. At present, all developed countries in the world have entered the council on Ageing, and many developing countries are or will soon enter the Council on Ageing. The incidence of cardiovascular and cerebrovascular diseases is also increasing rapidly, so the demand for antithrombotic drugs in the global market will increase, and the price of heparin sodium, as the basic raw material for the production of anticoagulant drugs, will naturally rise.
The guideline retail price of heparin sodium injection, which is used to prevent blood clotting in surgery, was raised from 4.5 yuan per 2 milliliters to 11.7 yuan in October last year. Drug pricing adjustments in reaction to changes in the cost at the same time also reflected the quality, especially after 08 "heparin incident", released in October 1, effect of the United States pharmacopoeia new standard not only improved the check method of heparin sodium, and comprehensively improve the acceptance standard of heparin, also further strengthen the production and quality management in enterprises, So the heparin sodium that finally flows into the market is of high potency, good quality, and the price keeps rising.
In recent years, developed countries in Europe and America were the main export markets of China's heparin sodium API. However, in recent years, some eastern European countries, such as Romania, Poland, Hungary and Bulgaria, as well as Nordic countries, such as Denmark and Finland, have also become emerging export markets of China's heparin sodium API, and the export speed is fast. The price of heparin sodium is affected by market supply and demand factors and rise again and again.
